Tempus Stock
Precision Medicine Solutions
Sign up today and learn more about Tempus Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Tempus Stock
Tempus is a technology-enabled precision medicine solutions company that has built an operating system to battle cancer. It is on a mission to redefine how genomic data is used in a clinical setting. Their goal is for each patient to benefit from the treatment of others who came before by enabling physicians to deliver personalized cancer care for patients through interactive analytical and machine learning platform. Eric Lefkofsky founded it in 2015 and is headquartered in Chicago, Illinois.
Investors
Magic Leap, Nuro, TAE Technologies, Tempus, Niantic, Symphony Communication Services, Ionic Security, Commonwealth Fusion, Trifacta, Barefoot Networks
New Enterprise Associates
Robinhood, Databricks, Jet, TAE Technologies, Scopely, Bloom Energy, Opendoor, Radiology Partners, DataRobot, Tempus
Novo Holdings
Revolution
Scopely, Tempus, Aura Financial Corporation, Sweetgreen, StockX, Tala, Optoro, DraftKings, BigCommerce, Uptake Technologies
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Funding History
| September 2015 | $10.0M |
|---|---|
| June 2016 | $10.0M |
| November 2016 | $10.0M |
| April 2017 | $30.0M |
| September 2017 | $70.0M |
| March 2018 | $80.0M |
| August 2018 | $111M |
| April 2019 | $200M |
| February 2020 | $97.3M |
| November 2020 | $409M |
Management
Chief Executive Officer
Eric Lefkofsky
Chief Financial Officer
Jim Rogers
Chief Technology Officer
Shane Colley
Press
bit - Aug, 5 2021
Tempus to open lab in Durham, North Carolinabiospace - Jul, 28 2021
Tempus Unveils Its Scalable Tumor Organoid Screening Platform In Cell Reports Studygenomeweb - May, 21 2021
Tempus Lens Platformbioworld - Mar, 24 2021
Tempus wins breakthrough status for AI-based tool to detect atrial fibrillationgenomeweb - Feb, 12 2021
New Products Posted to GenomeWeb: Tempus, Active Motif, Immudex, Zymo Research, Moremedcitynews - Feb, 11 2021
How Tempus’ corporate counsel views healthcare innovation: A Q&A with Maggie HustonEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
